ANTICANCER COMPOSITIONS

The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but...

Full description

Saved in:
Bibliographic Details
Main Authors MENSCH, Jurgen, BERTELS, Johny
Format Patent
LanguageEnglish
Published 29.11.2018
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMCAS, a poly(meth)acrylate copolymer, and mixtures thereof. In one aspect, these formulations comprise a granulate of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMC AS, a poly(meth)acrylate copolymer, and mixtures thereof.
Bibliography:Application Number: SG20181109680Q